Literature DB >> 24919183

The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features.

Myriam Chevarie-Davis1, Yasser Riazalhosseini, Madeleine Arseneault, Armen Aprikian, Wassim Kassouf, Simon Tanguay, Mathieu Latour, Fadi Brimo.   

Abstract

Papillary renal cell carcinomas (pRCC) are classically divided into type 1 and 2 tumors. However, many cases do not fulfill all the criteria for either type. We describe the clinical, morphologic, and immunohistochemical (IHC) features of 132 pRCCs to better characterize the frequency and nature of tumors with overlapping features. Cases were reviewed and classified; IHC evaluation of CK7, EMA, TopoIIα, napsin A, and AMACR was performed on 95 cases. The frequencies of type 1, type 2, and "overlapping" pRCC were 25%, 28%, and 47%, respectively. The 2 categories of "overlapping" tumors were: (1) cases with bland cuboidal cells but no basophilic cytoplasm (type A); and (2) cases with predominantly type 1 histology admixed with areas showing prominent nucleoli (type B). The pathologic stage of "overlapping" cases showed concordance with type 1 tumors. Using the 2 discriminatory markers (CK7, EMA), "type A" cases were similar to type 1. Although the high-nuclear grade areas of "type B" tumors showed some staining differences from their low-nuclear grade counterpart, their IHC profile was closer to type 1. Single nucleotide polymorphism array results, although preliminary and restricted to only 9 cases (3 with overlapping features), also seemed to confirm those findings. In conclusion, we demonstrate that variations in cytoplasmic quality and/or presence of high-grade nuclei in tumors otherwise displaying features of type 1 pRCCs are similar in stage and IHC profile those with classic type 1 histology, suggesting that their spectrum might be wider than originally described.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24919183     DOI: 10.1097/PAS.0000000000000247

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Papillary Renal Cell Carcinomas Demonstrating Micropapillary Features: An Investigation Into the Diagnostic and Prognostic Implications.

Authors:  Beatriz Caraballo; Maha Abdulla; Sunder Sham; Guang-Qian Xiao; Pamela Unger
Journal:  Cureus       Date:  2022-05-12

2.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Authors:  Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou
Journal:  Mod Pathol       Date:  2021-03-04       Impact factor: 8.209

3.  iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma.

Authors:  Jin Wook Hwang; Christophe Desterke; Olivier Féraud; Stephane Richard; Sophie Ferlicot; Virginie Verkarre; Jean Jacques Patard; Julien Loisel-Duwattez; Adlen Foudi; Frank Griscelli; Annelise Bennaceur-Griscelli; Ali G Turhan
Journal:  Int J Mol Sci       Date:  2019-09-30       Impact factor: 5.923

4.  Papillary Renal Cell Carcinoma in Lynch/Muir-Torre Syndrome with Germline Pathogenic Variant in MSH6 and Molecular Analysis: Report of a Case and Review of the Literature.

Authors:  Yu Yang; Shweta Dhar; Jennifer Taylor; Bhuvaneswari Krishnan
Journal:  J Kidney Cancer VHL       Date:  2021-04-21

5.  Papillary renal neoplasm with reverse polarity: A clinicopathological and molecular genetic characterization of 16 cases with expanding the morphologic spectrum and further support for a novel entity.

Authors:  Miaomiao Shen; Xiaona Yin; Yanfeng Bai; Huizhi Zhang; Guoqing Ru; Xianglei He; Xiaodong Teng; Guorong Chen; Ming Zhao
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

Review 6.  Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.

Authors:  Benjamin L Maughan
Journal:  Curr Oncol Rep       Date:  2022-04-19       Impact factor: 5.945

7.  Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.

Authors:  Ting Liu; Man Zhang; Deming Sun
Journal:  Biomed Res Int       Date:  2020-07-25       Impact factor: 3.411

8.  Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma.

Authors:  Zhuolun Sun; Changying Jing; Chutian Xiao; Tengcheng Li; Yu Wang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

9.  Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.

Authors:  Paari Murugan; Liwei Jia; Renzo G Dinatale; Melissa Assel; Nicole Benfante; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; Judy Sarungbam; S Joseph Sirintrapun; A Ari Hakimi; Paul Russo; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter
Journal:  Mod Pathol       Date:  2021-12-23       Impact factor: 8.209

10.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.